Neuron23
Last verified 2026-06-05. JSON
The funding figures on this page are attributed, not sourced: a publisher is on record but no document URL is. How we mark provenance.
| Total raised | $310.0Mattributed |
|---|---|
| Latest round | series-d+, $96.5M, 2025-06-01attributed |
| Founded | 2016 |
| Headquarters | South San Francisco, United States |
| Industry | bio |
| Stage | series-b+ |
| Website | neuron23.com |
Neuron23 is a clinical-stage biotech company developing precision medicines for neurological and immunological diseases, with a focus on Parkinson's. It serves patients with genetically defined disease such as LRRK2-driven Parkinson's. Its differentiator is machine-learning-based patient selection to find people most likely to respond.
Funding rounds
| Date | Round | Amount | Lead |
|---|---|---|---|
| 2025-06-01 | series-d+ | $96.5M | undisclosed |
Detected tech stack
adobe fonts, cloudflare, cloudflare bot management, contact form 7 6.1.6, doubleclick floodlight, google analytics, google tag manager, hsts, http/3, jquery migrate 3.4.1, jsdelivr, recaptcha
Provenance
| Fact | Status | Basis |
|---|---|---|
| Series D+, $96.5M | attributed | crunchbase named as publisher. No document URL on file. |
| Total raised $310.0M | attributed | crunchbase named as publisher. No document URL on file. |
| Company existence | self-reported | neuron23.com, read 2026-06-05 |
| Description | self-reported | neuron23.com, read 2026-06-05 |
Nothing on this page is sourced yet. A sourced fact links to a document that states it.
Change history
No change recorded since records began on 2026-09-24.